Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2011

View Archived Issues

Naftopidil has effects on stromal and cancer cells

New Wnt signaling inhibitors JW-74 and JW-67 inhibit tumor growth in vivo

New adenylate cyclase type 1 inhibitor NB-001 shows promise to treat neuropathic/inflammatory pain

Boehringer Ingelheim divulges new cannabinoid CB2 receptor agonists

BioCryst reports on phase III peramivir trials in influenza

Phase III data show benefits of Exparel after bunionectomy

PHD finger protein 6 is a tumor suppressor protein in AML

Vitae Pharma describes new 11-beta-HSD1 inhibitors

Adolor launches second phase II trial of ADL-5945 for opioid-induced constipation

New beta-secretase 1 inhibitors discovered at AstraZeneca

Cephalon patents new histamine H3 receptor antagonists/inverse agonists

Sirona Biochem reports on its sodium/glucose cotransporter 2 inhibitor for type 2 diabetes

Neovacs begins phase II TNF-K-005 trial of TNF-kinoid in Crohn's disease

Secondary endpoint met in phase III Corlux trial in Cushing's syndrome

Nabriva completes recruitment in phase II trial of BC-3781

Chugai grants Circadian Technologies global license to VEGF-D program

Abbott withdraws European MAA for Ozespa

Eli Lilly's Byetta is approved in Canada for type 2 diabetes

TransPharma Medical's ViaDerm becomes ViaDor

Phase III SUCCEED trial of oral ridaforolimus achieves primary endpoint

RG-7204 improves survival in phase III BRIM3 trial

Protalix provides update on programs in Gaucher's disease and Fabry's disease

Merck & Co. claims new inhibitors of Egl nine homolog 1, 2 and 3

New inhibitors discovered of polyamine transport into cancer cells

Astex Therapeutics begins first-in-human study of anticancer drug LEE-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...